ASND — Ascendis Pharma A/S
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on ASND
| date | signal | measured base rate |
|---|---|---|
| 2026-07-13 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-06-26 | Volume shock without a price move price | -1.33% over 21 days · t = -4.53 · n = 16,432 statistically distinguishable from its control group |
| 2026-06-25 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-06-17 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-01 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-04-29 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-14 | BIENAIME JEAN JACQUES Director | Open-market purchase | 1.1K | 245.85 | 270.4K |
| 2026-08-14 | BIENAIME JEAN JACQUES Director | Open-market purchase | 900 | 246.91 | 222.2K |
| 2026-06-02 | SMITH SCOTT THOMAS EVP & Chief Financial Officer | Open-market purchase | 100 | 219.00 | 21.9K |
| 2026-05-29 | SMITH SCOTT THOMAS EVP & Chief Financial Officer | Open-market purchase | 250 | 223.32 | 55.8K |
| 2026-05-29 | BIENAIME JEAN JACQUES Director | Open-market purchase | 200 | 223.76 | 44.8K |
| 2026-05-29 | BIENAIME JEAN JACQUES Director | Open-market purchase | 200 | 222.30 | 44.5K |
| 2026-05-29 | BIENAIME JEAN JACQUES Director | Open-market purchase | 100 | 223.50 | 22.4K |
| 2026-05-26 | BIENAIME JEAN JACQUES Director | Open-market purchase | 200 | 239.37 | 47.9K |
| 2026-05-26 | BIENAIME JEAN JACQUES Director | Open-market purchase | 200 | 236.24 | 47.2K |
| 2026-05-11 | JENSEN FLEMMING STEEN See Remarks | Open-market sale | 19.5K | 238.49 | 4.6M |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 2.4B | 10.3M |
| Avoro Capital Advisors LLC | 1.2B | 5.1M |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 1.1B | 4.8M |
| FMR LLC | 886.7M | 3.9M |
| Artisan Partners Limited Partnership | 738.8M | 3.2M |
| FRANKLIN RESOURCES INC | 469.3M | 2.1M |
| Capital International Investors | 448.0M | 2.0M |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 425.6M | 1.9M |
| WELLINGTON MANAGEMENT GROUP LLP | 402.0M | 1.8M |
| PERCEPTIVE ADVISORS LLC | 350.3M | 1.5M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| SCHEDULE 13G/A | 2026-08-13 | — | on EDGAR ↗ |
| 6-K | 2026-08-13 | 2026-08-13 | on EDGAR ↗ |
| 6-K | 2026-08-13 | 2026-06-30 | on EDGAR ↗ |
| 6-K | 2026-08-12 | 2026-08-12 | on EDGAR ↗ |
| 6-K | 2026-08-06 | 2026-08-06 | on EDGAR ↗ |
| 6-K | 2026-07-15 | 2026-07-15 | on EDGAR ↗ |
| 6-K | 2026-06-30 | 2026-06-30 | on EDGAR ↗ |
| 6-K | 2026-06-29 | 2026-06-29 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript · 2026-08-20
- Ascendis Pharma A/S reports Q2 results · 2026-08-13
Ask the AI about ASND
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →